In vivo, A3 treatment was shown to significantly increase the proportion of M1 macrophages in tumor tissues, elevate IL-12 levels, and reduce VEGF expression, ultimately resulting in suppressed tumor growth and decreased angiogenesis (Yin et al., 2021). This evidence concerns the gene VEGFA and neoplasm.